Upstream Bio (UPB) Change in Receivables (2023 - 2026)
Upstream Bio (UPB) posted quarterly Change in Receivables of $366000.0 for Q1 2026, up 878.72% year-over-year from $37395.7 in Q1 2025, and up 2540.0% quarter-over-quarter from -$15000.0 in Q4 2025.
Upstream Bio (UPB) Change in Receivables (2023 - 2026) Analysis & Trends
Upstream Bio's Change in Receivables history runs 4 years deep, the most recent figure standing at $366000.0 for Q1 2026.
- In Q1 2026, Change in Receivables rose 878.72% year-over-year to $366000.0; the TTM figure through Mar 2026 stood at $468000.0 (up 372.09% YoY), while the FY2025 annual figure was $55000.0, down 89.32% from the prior year.
- Change in Receivables for Q1 2026 stood at $366000.0, up from -$15000.0 in the prior quarter.
- The five-year high for Change in Receivables was $640000.0 in Q1 2024, with the low at -$254000.0 in Q3 2025.
- The 4-year median for Change in Receivables is -$4500.0 (2024), against an average of $76900.0.
- The sharpest annual moves came in 2025 and 2026: Change in Receivables tumbled 361.86% in 2025, then surged 878.72% in 2026.
- Upstream Bio's Change in Receivables stood at -$167000.0 in 2023, then soared by 103.59% to $6000.0 in 2024, then plunged by 350.0% to -$15000.0 in 2025, then soared by 2540.0% to $366000.0 in 2026.
- Business Quant data shows UPB's Change in Receivables at $366000.0 in Q1 2026, -$15000.0 in Q4 2025, and -$254000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 117.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -483,662.49 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 31.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 37.16 Mn |
| 10 | Upstream Bio | 387.23 Mn | 387.23 Mn | -3.29 Mn | -262,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -262,000.00 |
| Jun 30, 2026 | -262,000.00 |
| Mar 31, 2026 | 366,000.00 |
| Mar 31, 2026 | 366,000.00 |
| Dec 31, 2025 | -15,000.00 |
| Dec 31, 2025 | -15,000.00 |
| Sep 30, 2025 | -254,000.00 |
| Sep 30, 2025 | -254,000.00 |
| Jun 30, 2025 | 371,000.00 |
| Jun 30, 2025 | 371,000.00 |
| Mar 31, 2025 | -47,000.00 |
| Mar 31, 2025 | -47,000.00 |
| Dec 31, 2024 | 6,000.00 |
| Dec 31, 2024 | 6,000.00 |
| Sep 30, 2024 | 97,000.00 |
| Sep 30, 2024 | 97,000.00 |
| Jun 30, 2024 | -228,000.00 |
| Jun 30, 2024 | -228,000.00 |
| Mar 31, 2024 | 640,000.00 |
| Mar 31, 2024 | 640,000.00 |